Cosmo Bio Company,Limited
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Cosmo Bio Company,Limited owes ¥0.19 for every ¥1 it owns. Net profit rose 29% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Dec 2025.
P/E ratio
19.2Investors pay ¥19.2 for every ¥1 of Cosmo Bio Company,Limited's yearly profit, higher than 66% of Healthcare companies in Japan.
P/B ratio
0.72The share price is 0.72 times Cosmo Bio Company,Limited's book value per share, lower than 90% of Healthcare companies in Japan.
Market cap
¥7.0 BThe total market value of all of Cosmo Bio Company,Limited's shares at today's price (share price × number of shares), smaller than 70% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥9.8 BWhat Cosmo Bio Company,Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥1,712Net worth divided by the number of shares. The share price of ¥1,228 is 0.7 times this, which is the P/B above.
Return on equity (ROE)
3.7%Cosmo Bio Company,Limited earned 3.7% on its shareholders' money over the last year, lower than 66% of Healthcare companies in Japan.
Owes vs Owns
0.19×Cosmo Bio Company,Limited owes ¥0.19 for every ¥1 it owns (low), lower than 78% of Healthcare companies in Japan.
Dividend yield
4.07%Cosmo Bio Company,Limited pays 4.07% of its share price as dividends a year, higher than 85% of dividend-paying Healthcare companies in Japan.
Revenue growth
+7%Revenue rose 7% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Profit growth
+29%Net profit rose 29% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Profit margin
3.1%Cosmo Bio Company,Limited keeps ¥3 of every ¥100 of revenue as net profit.
Cash quality
1.8×Cash from Cosmo Bio Company,Limited's business was 1.8× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashCosmo Bio Company,Limited held ¥2.9 B more cash than debt (net cash) at Dec 2025.
Questions
What is Cosmo Bio Company,Limited's P/E ratio?
Investors pay ¥19.2 for every ¥1 of Cosmo Bio Company,Limited's yearly profit, higher than 66% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cosmo Bio Company,Limited: ¥7.0 B ÷ ¥9.8 B (30 Jun 2026) = 0.7.
What is Cosmo Bio Company,Limited's return on equity?
Cosmo Bio Company,Limited earned 3.7% on its shareholders' money over the last year, lower than 66% of Healthcare companies in Japan.
How much does Cosmo Bio Company,Limited owe compared with what it owns?
Cosmo Bio Company,Limited owes ¥0.19 for every ¥1 it owns (low), lower than 78% of Healthcare companies in Japan.
Does Cosmo Bio Company,Limited pay a dividend?
Yes. Cosmo Bio Company,Limited pays 4.07% of its share price as dividends a year, higher than 85% of dividend-paying Healthcare companies in Japan.
Is Cosmo Bio Company,Limited's revenue growing?
Revenue rose 7% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.